JP2007505916A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505916A5
JP2007505916A5 JP2006527026A JP2006527026A JP2007505916A5 JP 2007505916 A5 JP2007505916 A5 JP 2007505916A5 JP 2006527026 A JP2006527026 A JP 2006527026A JP 2006527026 A JP2006527026 A JP 2006527026A JP 2007505916 A5 JP2007505916 A5 JP 2007505916A5
Authority
JP
Japan
Prior art keywords
alkoxy
alkyl
halo
cycloalkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006527026A
Other languages
English (en)
Other versions
JP4928941B2 (ja
JP2007505916A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/030375 external-priority patent/WO2005042478A2/en
Publication of JP2007505916A publication Critical patent/JP2007505916A/ja
Publication of JP2007505916A5 publication Critical patent/JP2007505916A5/ja
Application granted granted Critical
Publication of JP4928941B2 publication Critical patent/JP4928941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. 式(I):
    Figure 2007505916
    〔式中、
    Xは共有結合、S、またはOから選択され、
    YはSまたはOであり、
    −−−−W−−−−は、=CH−、−CH=、−CH2−、−CH2−CH2−、=CH
    −CH2−、−CH2−CH=、=CH−CH=、および−CH=CH−から選択される
    基を表し、
    ZはO、CH、およびCH2から選択され、ただしYがOの場合には、ZはOであり、
    1およびR2はH、C1-3アルキル、C1-3アルコキシ、ハロ、およびNRab
    から独立して選択され、ここでRaおよびRbは独立してHまたはC1-3アルキルであ
    り、
    3およびR4はH、ハロ、シアノ、ヒドロキシ、アセチル、C1-5アルキル、C1-
    4アルコキシ、およびNRcdから独立して選択され、ここでRcおよびRdは独立し
    てHまたはC1-3アルキルであり、ただしR3およびR4は双方がHではなく、
    5はハロ、フェニル、フェノキシ、(フェニル)C1-5アルコキシ、(フェニル)C
    1-5アルキル、C2-5ヘテロアリールオキシ、C2-5ヘテロアリールC1-5アル
    コキシ、C2-5ヘテロシクリルオキシ、C1-9アルキル、C1-8アルコキシ、C2
    -9アルケニル、C2-9アルケニルオキシ、C2-9アルキニル、C2-9アルキニル
    オキシ、C3-7シクロアルキル、C3-7シクロアルコキシ、C3-7シクロアルキル
    −C1-7アルキル、C3-7シクロアルキル−C1-7アルコキシ、C3-7シクロア
    ルキルオキシ−C1-6アルキル、C1-6アルコキシ−C1-6アルキル、C1-5
    ルコキシ−C1-5アルコキシ、またはC3-7シクロアルキルオキシ−C1-7アルコ
    キシから選択され、
    −−−−W−−−−が−CH=、−CH2−、−CH2−CH2−、−CH2−CH=、
    および−CH=CH−から選択される基を表す場合にはR6はHであり、または−−−−
    W−−−−が=CH−、=CH−CH2−、および=CH−CH=から選択される基を表
    す場合に、R6は存在せず、そして
    nは1または2である〕
    の化合物またはその製薬学的に許容され得る
JP2006527026A 2003-09-19 2004-09-16 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物 Active JP4928941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50414603P 2003-09-19 2003-09-19
US60/504,146 2003-09-19
PCT/US2004/030375 WO2005042478A2 (en) 2003-09-19 2004-09-16 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Publications (3)

Publication Number Publication Date
JP2007505916A JP2007505916A (ja) 2007-03-15
JP2007505916A5 true JP2007505916A5 (ja) 2007-11-08
JP4928941B2 JP4928941B2 (ja) 2012-05-09

Family

ID=34549183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527026A Active JP4928941B2 (ja) 2003-09-19 2004-09-16 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物

Country Status (30)

Country Link
US (9) US7301050B2 (ja)
EP (2) EP1667964B1 (ja)
JP (1) JP4928941B2 (ja)
KR (1) KR101111475B1 (ja)
CN (1) CN1882533B (ja)
AR (1) AR045773A1 (ja)
AT (1) ATE542793T1 (ja)
AU (1) AU2004285849B2 (ja)
BR (1) BRPI0414268B8 (ja)
CA (1) CA2539446C (ja)
CO (1) CO5680476A2 (ja)
CR (1) CR8301A (ja)
CY (1) CY1110555T1 (ja)
DE (1) DE602004022179D1 (ja)
DK (1) DK1667964T3 (ja)
EA (1) EA012241B1 (ja)
EC (1) ECSP066434A (ja)
ES (2) ES2328581T3 (ja)
HK (2) HK1092784A1 (ja)
IL (1) IL174398A (ja)
NO (2) NO338511B1 (ja)
NZ (1) NZ545943A (ja)
PL (1) PL1667964T3 (ja)
PT (1) PT1667964E (ja)
SG (1) SG145752A1 (ja)
SI (1) SI1667964T1 (ja)
TW (1) TWI336238B (ja)
UA (1) UA87467C2 (ja)
WO (1) WO2005042478A2 (ja)
ZA (1) ZA200603085B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1667964T3 (da) 2003-09-19 2009-10-26 Janssen Pharmaceutica Nv 4-((Phenoxyalkyl)thio)-phenoxyeddikesyrer og analoger
SG149041A1 (en) 2003-09-19 2009-01-29 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
ES2712052T3 (es) * 2008-10-17 2019-05-09 Cymabay Therapeutics Inc Métodos para reducir partículas de LDL pequeñas y densas
WO2014005671A1 (en) * 2012-07-06 2014-01-09 Merck Patent Gmbh Bimesogenic compounds and mesogenic media
JP2017505285A (ja) 2013-11-20 2017-02-16 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. ホモ接合性家族性高コレステロール血症の治療
AU2015231232B2 (en) 2014-03-20 2018-08-02 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2015157697A1 (en) 2014-04-11 2015-10-15 Cymabay Therapeutics, Inc. Treatment of nafld and nash
AU2015279905A1 (en) 2014-06-26 2017-02-02 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3681537A1 (en) 2017-09-13 2020-07-22 Novartis AG Combinations comprising fxr agonists
US20190105291A1 (en) 2017-09-26 2019-04-11 Cymabay Therapeutics, Inc. Treatment of cholestatic pruritus
US11497723B1 (en) * 2017-12-19 2022-11-15 Tony Antakly PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
US10702488B2 (en) * 2017-12-19 2020-07-07 Theriac Biomedical Inc. PPAR-γ activators, HDAC inhibitors and their therapeutical usages
JP2022507644A (ja) 2018-11-16 2022-01-18 サイマベイ・セラピューティクス・インコーポレイテッド Nafldおよびnashの併用治療
MX2021005725A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
CN112824380A (zh) * 2019-11-21 2021-05-21 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
KR20230107700A (ko) 2021-02-01 2023-07-17 사이머베이 쎄라퓨틱스, 인코퍼레이티드 셀라델파르에 의한 담관병증의 치료

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517051A (en) * 1964-03-20 1970-06-23 Merck & Co Inc Phenoxy substituted phenylacetic acids
US4109013A (en) * 1974-12-20 1978-08-22 Klinge Pharma Gmbh & Co. Substituted propanol-(2) derivatives of hydroxamic acids and the use thereof as hypolipemic drugs
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0056172B1 (en) * 1981-01-09 1985-04-03 FISONS plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) * 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
DE3366107D1 (en) * 1982-09-30 1986-10-16 Merck Frosst Canada Inc Leukotriene antagonists, their production, and compositions containing them
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) * 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
EP0562796A1 (en) 1992-03-23 1993-09-29 Terumo Kabushiki Kaisha Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
EP0888278B1 (en) 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetic agents
ES2241036T3 (es) * 1996-02-02 2005-10-16 MERCK & CO., INC. Procedimiento de tratamiento de diabetes y estados patologicos asociados.
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
DE69840510D1 (de) 1997-07-24 2009-03-12 Astellas Pharma Inc Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
DE69836980T2 (de) * 1997-12-19 2007-11-15 Merck & Co., Inc. Arylthiazolidindion-derivate
EP1171414A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
EP1194146B1 (en) * 1999-06-18 2006-07-19 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0003310D0 (en) * 2000-02-15 2000-04-05 Univ Sheffield Bone formation
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
MXPA03011201A (es) 2001-06-07 2004-02-26 Lilly Co Eli Moduladores de receptores activados por proliferadores de persoxisomas.
MXPA04000891A (es) * 2001-07-30 2004-05-21 Novo Nordisk As Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
EP1424330B1 (en) 2001-08-10 2011-09-28 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor delta
DK1445258T3 (da) 2001-10-12 2009-10-12 Nippon Chemiphar Co Aktivator for peroxisomproliferator-aktiveret receptor delta
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
EP1480957A1 (en) * 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
BR0314335A (pt) 2002-09-05 2005-07-26 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade
DE60333211D1 (de) 2002-10-28 2010-08-12 High Point Pharmaceuticals Llc Neue verbindungen und deren verwendung als ppar-modulatoren
PL376704A1 (pl) 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki przydatne w leczeniu chorób, w których pośredniczy PPAR
ES2384973T3 (es) 2003-02-14 2012-07-16 Biogen Idec Ma Inc. Un casete y vector de expresión para la expresión transitoria o estable de moléculas exógenas
US20060257987A1 (en) * 2003-08-20 2006-11-16 Gonzalez Valcarcel Isabel Cris Ppar modulators
SG149041A1 (en) 2003-09-19 2009-01-29 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
DK1667964T3 (da) * 2003-09-19 2009-10-26 Janssen Pharmaceutica Nv 4-((Phenoxyalkyl)thio)-phenoxyeddikesyrer og analoger
EA009804B1 (ru) 2003-10-31 2008-04-28 Янссен Фармацевтика Н.В. Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора (ppar)
DE602005020127D1 (de) 2004-04-21 2010-05-06 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
WO2006002802A1 (en) 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Phenyl derivatives comprising an acetylene group
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Similar Documents

Publication Publication Date Title
JP2007505916A5 (ja)
JP2007510619A5 (ja)
EP2592070A3 (en) Tetrazole-substituted arylamides
JP2005508905A5 (ja)
JP2007534702A5 (ja)
JP2008546770A5 (ja)
JP2003506347A5 (ja)
JP2010540525A5 (ja)
JP2005053931A5 (ja)
JP2008517020A5 (ja)
JP2002527396A5 (ja)
JP2008520662A5 (ja)
JP2007516205A5 (ja)
JP2001526218A5 (ja)
JP2011529502A5 (ja)
JP2005538089A5 (ja)
JP2008536833A5 (ja)
EP2308828A3 (en) CaSR antagonist
JP2005511697A5 (ja)
JP2002535387A5 (ja)
JP2002525323A5 (ja)
JP2008542386A5 (ja)
JP2003502367A5 (ja)
JP2007519618A5 (ja)
JP2012505905A5 (ja)